Comprehensive characterization of the integrin family across 32 cancer types

Abstract

Integrin genes widely involve in tumorigenesis. Yet, a comprehensive characterization of integrin family and their interactome on the pan-cancer level is lacking. Here, we systematically dissect integrin family in nearly 10000 tumors across 32 cancer types. Globally, integrins represent a frequently altered and misexpressed pathway, with alteration and dysregulation overall being protumorigenic. Expression dysregulation, better than mutational landscape, of integrin family successfully identifies a subgroup of aggressive tumors demonstrating a high level of proliferation and stemness. We identify that several molecular mechanisms jointly regulate integrin expression in a context-dependent manner. For potential clinical usage, we construct a weighted score, integrinScore, to measure integrin signaling patterns in individual tumors. Remarkably, integrinScore consistently correlates with predefined molecular subtypes in multiple cancers, with integrinScore high tumors being more aggressive. Importantly, integrinScore is cancer-dependently and closely associated with proliferation, stemness, tumor microenvironment, metastasis, and immune signatures. IntegrinScore also predicts patients response to immunotherapy. By mining drug databases, we unravel an array of compounds that may serve as integrin signaling modulators. Finally, we build a user-friendly database to facilitate researchers to explore integrin-related knowledge. Collectively, we provide a comprehensive characterization of integrins across cancers, which offers gene- and cancer-specific rationales for developing integrin-targeted therapy.